Anti-ANG-2 therapy, in combination with monoclonal antibodies simultaneously targeting other angiogenic factors, including VEGF, TIE2, or ANG-1, may enhance the effect on lung cancer therapy as well. This evidence concerns the gene ANGPT2 and lung carcinoma.